Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3586 to 3600 of 8905 results

  1. Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment (HTG753)

    Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.

    HealthTech guidance
    Published
    9 July 2025
    View recommendations

    Sections for HTG753

  2. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

    HealthTech guidance
    Published
    19 June 2025
    View recommendations

    Sections for HTG751

  3. Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)

    Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.

    HealthTech guidance
    Published
    6 May 2025
    View recommendations

    Sections for HTG747

  4. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

    HealthTech guidance
    Published
    8 May 2019
    View recommendations

    Sections for HTG508

  5. DMD Care UK's guideline on respiratory care: NICE review (NR2)

    NICE has reviewed DMD Care UK’s guideline on respiratory care for Duchenne muscular dystrophy. We think the guideline from DMD Care UK is a useful resource that will help healthcare professionals improve care in this area

    NICE review
    Published
    17 December 2025

  6. NICE and health inequalities

    Health inequalities are differences in health across the population, and between different groups in society, that are systematic, unfair and avoidable.

  7. Involving you in the development of our guidance

    Involving you in the development of NICE guidance.

  8. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  9. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  10. Data collection agreement

    Home What NICE does Our guidance About technology appraisal guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":

  11. Getting involved as a voluntary and community sector organisation

    Getting involved with NICE as a voluntary and community sector organisation

  12. Public health advisory committees

    The standing committees were responsible for the development of our public health guidance.

  13. Consultations

    People can comment on our guidance at specific stages in its development.

  14. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  15. Health inequalities: the wider picture

    Health inequalities can be experienced by people grouped by a range of different factors.